Stockscreener 앱 받기
33.35
1.83%
0.60
전일 마감가:
$32.75
열려 있는:
$33
하루 거래량:
583.63K
Relative Volume:
1.85
시가총액:
$1.69B
수익:
$357.71M
순이익/손실:
$-20.10M
주가수익비율:
-80.63
EPS:
-0.4136
순현금흐름:
$28.67M
1주 성능:
+1.06%
1개월 성능:
-7.90%
6개월 성능:
-6.70%
1년 성능:
+14.60%
1일 변동 폭
$32.99
$33.92
1주일 범위
$32.00
$34.71
52주 변동 폭
$23.15
$40.71
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
IMCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
33.35 | 1.65B | 357.71M | -20.10M | 28.67M | -0.4136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 업그레이드 | UBS | Sell → Buy |
| 2025-10-31 | 개시 | Wells Fargo | Overweight |
| 2025-09-18 | 재개 | Guggenheim | Neutral |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-05-27 | 개시 | Deutsche Bank | Buy |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Columbia Banking System, Inc. (NASDAQ:COLB) Given Average Recommendation of “Hold” by Analysts - Defense World
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Immunocore (NASDAQ:IMCR) Upgraded at Zacks Research - Defense World
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Immunocore outlines 2026 strategy at J.P. Morgan conference - Investing.com
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Immunocore (NASDAQ:IMCR) Shares Gap UpWhat's Next? - MarketBeat
UBS assumes coverage on Immunocore stock with Buy rating, $55 target - Investing.com
UBS assumes coverage on Immunocore stock with Buy rating, $55 target By Investing.com - Investing.com South Africa
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Hudson Bay Capital Management LP Sells 49,382 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Bellevue Group AG Increases Stake in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eschler Asset Management LLP Invests $1.26 Million in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
1,024,288 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Purchased by BVF Inc. IL - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Position Lowered by Armistice Capital LLC - MarketBeat
Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance - Finviz
Immunocore (NASDAQ:IMCR) Sets New 52-Week High – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 1-Year HighHere's What Happened - MarketBeat
Schroder Investment Management Group Boosts Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore stock hits 52-week high at 40.71 USD By Investing.com - Investing.com India
Immunocore stock hits 52-week high at 40.71 USD - Investing.com
Immunocore (NASDAQ:IMCR) Shares Gap DownHere's What Happened - MarketBeat
Immunocore Holdings stock hits 52-week high at $40.53 - Investing.com
Immunocore Holdings stock hits 52-week high at $40.53 By Investing.com - Investing.com South Africa
Immunocore announces board and executive departures with no reported disagreements - Investing.com
Immunocore (NASDAQ:IMCR) Sets New 1-Year HighStill a Buy? - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 52-Week HighWhat's Next? - MarketBeat
Immunocore stock hits 52-week high at 39.5 USD - Investing.com
Immunocore at Jefferies Conference: Strategic Expansion and Innovation By Investing.com - Investing.com South Africa
Immunocore at Jefferies Conference: Strategic Expansion and Innovation - Investing.com
A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy - Sahm
Acadian Asset Management LLC Acquires 72,355 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Fiera Capital Corp Purchases 7,924 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Positive Hepatitis B Trial Data Might Change the Case for Investing in Immunocore Holdings (IMCR) - Sahm
Immunocore reports promising data for HBV treatment candidate By Investing.com - Investing.com South Africa
Immunocore reports promising data for HBV treatment candidate - Investing.com
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting - GlobeNewswire Inc.
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $60.89 - Defense World
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? - sharewise.com
State of New Jersey Common Pension Fund D Purchases New Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Y Intercept Hong Kong Ltd Makes New $1.62 Million Investment in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immunocore (NASDAQ:IMCR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
H.C. Wainwright reaffirms Buy rating on Immunocore stock at $100 target - Investing.com
TD Asset Management Inc Sells 9,590 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤노코어 홀딩스 주식 (IMCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Option Exercise |
17.46 |
572 |
9,987 |
572 |
| Berman David M | HEAD OF R&D |
Dec 04 '25 |
Sale |
40.26 |
31,341 |
1,261,789 |
0 |
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Sale |
40.14 |
572 |
22,960 |
0 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Option Exercise |
17.46 |
69,404 |
1,211,794 |
69,404 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Option Exercise |
17.46 |
5,521 |
96,397 |
5,521 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Sale |
40.12 |
69,404 |
2,784,488 |
0 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Sale |
40.09 |
5,521 |
221,337 |
0 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Option Exercise |
17.46 |
18,020 |
314,629 |
18,020 |
| Berman David M | HEAD OF R&D |
Nov 24 '25 |
Option Exercise |
17.46 |
100 |
1,746 |
100 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Sale |
40.03 |
18,020 |
721,341 |
0 |
4.73%
0.92%
자본화:
|
볼륨(24시간):